Recent disruptions in medical product supply chains have highlighted the need for stronger, more coordinated approaches to ensuring reliable access to medical products. Federal and private-sector leaders increasingly recognize the importance of building resilience, but there is great variability in how the concepts of medical supply chain resilience, criticality, and vulnerability are defined and measured.
To address this gap, Mathematica conducted a study that included a literature review, key informant interviews, and a technical expert panel of leaders from academia, industry, and government. The study identified common definitions and approaches to measurement and outlined common challenges and barriers to measuring medical supply chain resilience. Findings emphasize the importance of data transparency, cross-sector collaboration, and federal leadership to support building the resilience of medical product supply chains.
Related Products:
- 2025-2028 Draft Action Plan for Addressing Shortages of Medical Products and Critical Foods and Strengthening the Resilience of Medical Product and Critical Food Supply Chains (Jan 2025)
- Policy Considerations to Prevent Drug Shortages and Mitigate Supply Chain Vulnerabilities in the United States (Apr 2024)
- Medical Product Shortages in the United States: Demographic and Geographic Factors and Impacts (Jul 2024)
- Medical Device Supply Chains: An Overview and Description of Challenges During the COVID-19 Pandemic (Oct 2021)
- Prescription Drug Supply Chains: An Overview of Stakeholders and Relationships
- Linking Medical Product Manufacturing Locations with Natural Hazard Risk: Implications for the Medical Product Supply Chain (Jul 2024)
- Understanding the Impact and Costs Associated with Medical Device Shortages During the COVID-19 Pandemic on Providers, Health Systems, Patients, and Manufacturers (Jan 2025)
- An Examination of the Return on Investment of Generic Injectable Prescription Drugs (Dec 2024)
- Measuring Innovation of Medical Products (Sept 2025)